Pulmatrix Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Ted Raad
Chief executive officer
US$691.9k
Total compensation
CEO salary percentage | 82.0% |
CEO tenure | 4.9yrs |
CEO ownership | n/a |
Management average tenure | 4.9yrs |
Board average tenure | 4.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$692k | US$567k | -US$14m |
Sep 30 2023 | n/a | n/a | -US$16m |
Jun 30 2023 | n/a | n/a | -US$18m |
Mar 31 2023 | n/a | n/a | -US$18m |
Dec 31 2022 | US$1m | US$525k | -US$19m |
Sep 30 2022 | n/a | n/a | -US$22m |
Jun 30 2022 | n/a | n/a | -US$25m |
Mar 31 2022 | n/a | n/a | -US$24m |
Dec 31 2021 | US$1m | US$480k | -US$23m |
Sep 30 2021 | n/a | n/a | -US$19m |
Jun 30 2021 | n/a | n/a | -US$21m |
Mar 31 2021 | n/a | n/a | -US$19m |
Dec 31 2020 | US$2m | US$464k | -US$19m |
Sep 30 2020 | n/a | n/a | -US$20m |
Jun 30 2020 | n/a | n/a | -US$13m |
Mar 31 2020 | n/a | n/a | -US$20m |
Dec 31 2019 | US$823k | US$411k | -US$21m |
Sep 30 2019 | n/a | n/a | -US$21m |
Jun 30 2019 | n/a | n/a | -US$22m |
Mar 31 2019 | n/a | n/a | -US$20m |
Dec 31 2018 | US$707k | US$345k | -US$21m |
Sep 30 2018 | n/a | n/a | -US$21m |
Jun 30 2018 | n/a | n/a | -US$20m |
Mar 31 2018 | n/a | n/a | -US$20m |
Dec 31 2017 | US$963k | US$216k | -US$18m |
Compensation vs Market: Ted's total compensation ($USD691.89K) is above average for companies of similar size in the German market ($USD401.52K).
Compensation vs Earnings: Ted's compensation has been consistent with company performance over the past year.
CEO
Ted Raad (53 yo)
4.9yrs
Tenure
US$691,888
Compensation
Mr. Teofilo David Raad, also known as Ted, MBA, has been Director at Oxeia Biopharmaceuticals Inc. since 2021. Mr. Raad serves as Chief Executive Officer, President and Director at Pulmatrix, Inc. since Ma...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 4.9yrs | US$691.89k | no data | |
Interim CFO and Principal Accounting & Financial Officer | 2yrs | US$510.22k | no data | |
Founder | 21.3yrs | no data | no data |
4.9yrs
Average Tenure
68yo
Average Age
Experienced Management: 2PU's management team is considered experienced (4.9 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 4.9yrs | US$691.89k | no data | |
Independent Chairman | 8.8yrs | US$92.97k | 0% $ 0 | |
Member of Pulmazole Clinical Advisory Board | no data | no data | no data | |
Independent Director | 3.8yrs | US$50.56k | 0% $ 0 | |
Member of Pulmazole Clinical Advisory Board | no data | no data | no data | |
Independent Director | 4.4yrs | US$59.56k | 0.00068% $ 47.4 | |
Independent Director | 3.5yrs | US$58.06k | 0% $ 0 | |
Member of Pulmazole Clinical Advisory Board | no data | no data | no data | |
Member of Pulmazole Clinical Advisory Board | no data | no data | no data | |
Member of Pulmazole Clinical Advisory Board | no data | no data | no data | |
Chair of PUR1900 & PUR1800 Clinical Advisory Board | no data | no data | no data | |
Chair of PUR3100 (DHE) Clinical Advisory Board | no data | no data | no data |
4.4yrs
Average Tenure
53yo
Average Age
Experienced Board: 2PU's board of directors are considered experienced (4.4 years average tenure).